The fields of oncology and hematology are fast-paced. New studies are published every day, offering fresh information and insights into diseases and treatments. This emerging research changes the landscape of medical information on which clinicians base their decisions. In addition, doctors’ experiences and collaborations within clinics and hospitals evolve over time. This progression impacts how they run their practices, how they interact with their patients, and how they envision their future.
Insights into the varied factors that affect physicians’ treatment choices and decisions are a valuable commodity to experts in life sciences and pharmaceutical fields, as they are in unique positions to develop and market solutions to benefit patients’ and physicians. Information in medicine is exchanged at a dizzying pace. It can be difficult for anyone inside or outside the field to discern patterns or unearth key takeaways.
While the most straightforward solution might seem to be face-to-face meetings with physicians, finding time and opportunities to interface with these key opinion leaders (KOLs) in medicine can be a challenge. Reduced staffing, increasing patient numbers, and administrative workload, as well as regulations on contact between pharmaceutical industry representatives and clinicians, have created barriers to communication that are sometimes real, sometimes perceived. While embracing ethical standards is paramount when considering patient care, communication between the life sciences and medical fields is vital to connect the realities of clinical medicine to the possibilities of treatment. Understanding the challenges the patient faces can also help shape the resources pharmaceutical experts can develop and offer.
Finding ways to bridge this information gap is increasingly important in the life sciences, pharmaceutical, and medical device arenas. Resources that can relay the current discussions and debates in medicine can help life sciences and pharmaceutical industry experts keep a finger on the pulse of the specialties most important to them, such as rare cases or clinical hurdles and patient challenges, with a level of detail they might not otherwise have.
Insights Reports Bridge the Gap
Insights reports are one such resource. These reports summarize discussions held at various events, and detail insights gained from specific invitation-only conversations with KOLs in their areas of expertise. Reports that cover the spectrum of pertinent medical topics are valuable sources of industry-relevant information.
The reports may offer a broad perspective on the treatment of a particular disease, or review a certain class of pharmaceutical drugs and their overall role in treatment. Ongoing clinical trials and current trends in the field are other important topics that may be discussed at these roundtable events. Gaining insights from these kinds of expert-led discussions is impactful to our understanding of the current trends in medicine and the effects on physicians and patients.
These discussions may also focus on a single type of pharmaceutical drug, one form of cancer, or a specific area of research. Narrow-focus topics such as these offer insights and opinions that may not be available elsewhere, and are beneficial in gaining a broader view of a field. Because medical practices differ by region, insights reports summarizing information from medical professionals in small communities and regions with distinct cultural differences are quite valuable.
Emerging Paradigms in Care Series (EPICS)
Emerging Paradigms in Care Series (EPICS) reports cover current developments in various disease types and their underlying pathways. They offer the opportunity to deepen our understanding of a disease’s progression and the chemical and biologic pathways at the root of it. Grasping the context of this kind of emerging medical research is the first step toward better understanding current therapeutic practices and predicting trends in future treatment. These discussions are directly relevant to the current and future marketplace.
Each indication-specific EPICS report is based on a 2-day clinical collaboration in which a group of internationally recognized KOLs openly discuss a range of topics. The sessions are valuable opportunities for experts in the field to exchange information and ideas free from commercial bias. The resulting EPICS report includes the meeting highlights, key takeaways, and any recommendations from the group.
One valuable aspect of these reports is the opportunity for better comprehension of the chosen topic. But you can also build on this comprehensive understanding to sharpen your strategic awareness of a product. Ideas from these discussions may spark a new area of interest. You may be inspired to develop a new approach to a challenge. As these high-level talks end, multiple pathways of opportunity can begin.
Community Access Scientific Exchange Series (CASES)
Clinical solutions must be culturally relevant and inclusive. Much of our perspective may be built on mainstream practices and trends. Broadening our awareness of less-common methods and culturally specific tendencies is vital in understanding how treatments and medical devices impact patients across the full spectrum of care.
Community Access Scientific Exchange Series (CASES) reports are derived from region- and topic-specific discussions among community physicians regarding medical trends, tendencies, and challenges. This focused information offers a unique perspective on the particular region’s treatment and marketing environment.
The CASES reports home in on particular treatment patterns, treatment decisions, and care trends in a community practice setting. The takeaway is a better understanding of the factors that contribute to a region’s trends and practices and the downstream effects on community health.
CASES reports provide a detailed understanding of how a particular region or community’s experience or views differ from the broader outlook. They also present targeted information on patterns in the data from these regions and participants’ views on how the data are interpreted.
